Page 92 - BH-3-1
P. 92

Brain & Heart                                                     Brain lesions with PROKR2 microduplication



               from systolic overload-induced congestive heart failure.   13.  Cheng MY, Lee AG, Culbertson C, et al. Prokineticin 2 is an
               Circulation. 2014;129:1397-1406.                   endangering mediator of cerebral ischemic injury. Proc Natl
                                                                  Acad Sci U S A. 2012;109(14):5475-5480.
               doi: 10.1161/CIRCULATIONAHA.113.002209
                                                                  doi: 10.1073/pnas.1113363109
            7.   Balachandran S, Roberts PC, Kipperman T,  et al. Alpha/
               beta interferons potentiate virus-induced apoptosis through   14.  Younes H, Kyritsi I, Mahrougui Z, Benharouga M,
               activation of the FADD/Caspase-8 death signaling pathway.   Alfaidy N, Marquette C. Effects of prokineticins on cerebral
               J Virol. 2000;74(3):1513-1523.                     cell function and blood-brian barrier permeability. Int J Mol
                                                                  Sci. 2023;24:15428.
               doi: 10.1128/jvi.74.3.1513-1523.2000
                                                                  doi: 10.3390/ijms242015428
            8.   Boriushkin E, Wang JJ, Li J, Bhatta M, Zhang S. P58
                                                         IPK
               suppresses NLRP3 inflammasome activation and IL-1ß   15.  Dhar A. The role of PKR as a potential target for treating
               production via inhibition of PKR in  macrophages. Sci   cardiovascular disease. Curr Cardiol Rev. 2017;13:28-31.
               Rep. 2016;6:25013.
                                                                  doi: 10.2174/1573403x12666160526122600
               doi: 10.1038/srep25013
                                                               16.  Lalani SR, Thakuria JV, Cox GF, et al. 20p12.3 Microdeletion
            9.   Wang Y, Men M, Xie B, et al. Inihibition of PKR protects   predisposes to Wolff-Parkinson-White syndrome with
               against H O -induced injury on neonatal cardiac    variable neurocognitive deficits.  J  Med Genet.  2009;46:
                          2
                        2
               myocytes by attenuating apoptosis and inflammation. Sci   168-175.
               Rep. 2016;6:38753.
                                                                  doi: 10.1136/jmg.2008.061002
               doi: 10.1038/srep38753
                                                               17.  Mills KI, Anderson J, Levy PT, et al. Duplication of 20p12.3
            10.  Stewart MJ, Blum MA, Sherry B. PKR’s protective role in   associated with familial Wolff-Parkinson-White syndrome.
               viral myocarditis. Virology. 2003;314:92-100.      Am J Med Genet Part A. 2012;161A:137-144.
               doi: 10.1016 S0042-6822(03)j00414-8                doi: 10/1002/ajmg.a.35701
            11.  Lin SS, Lee DCW, Law AHY, Fang JW, Chua DTT, Lau ASY.   18.  Xiao J, Tan Y, Li Y, Luo Y. The specific protein kinase R (PKR)
               A role for protein kinase PKR in the mediation of Epstein-  inhibitor C16 protects neonatal hypoxia-ischemia brain
               Barr virus latent membrane protein-1-induced IL-6 and   damages by inihibiting neuroinflammation in a neonatal rat
               IL-10 expression. Cytokine. 2010;50(2):210-219.    model. Med Sci Monit. 2016;22:5074-5081.
               doi: 10.1016/j.cyto.2010.01.008                    doi: 10.12659/MSM.898139
            12.  Bleiblo F, Michael P, Brabant D, et al. Bacterial RNA induced   19.  Reynaud D, Sergent F, Abi Nahed R, et al. Evidence-based
               myocyte cellular dysfunction through the activation of PKR.   view of safety and effectiveness of prokineticin receptors
               J Thorac Dis. 2012;4(2):114-125.                   antagonists during pregnancy. Biomedicines. 2021;9:309.
               doi: 10.3978/j.issn.2072-1439.2012.01.07           doi: 10.3390/biomedicines9030309
































            Volume 3 Issue 1 (2025)                         5                                doi: 10.36922/bh.4281
   87   88   89   90   91   92   93   94   95   96   97